Immunotherapy in renal cancer: present in the context of the past

04/2020

Doc. MUDr. Jan Novotný, Ph.D.

Onkologi, Sunderby Sjukhus, Luieá, Švédsko

 

SUMMARY

Metastatic renal carcinoma belongs to the class of malignancies in which an immunologic response is described, observed and used as a treatment strategy. In 2019, four randomized controlled trials studying four novel immunotherapy-based regimens have been published (nivolumab with ipilimumab, atezolizumab plus bevacizumab, avelumab plus axitinib and pembrolizumab with axitinib). Some of these regimens exert a survival advantage to the appropriately selected patients. All aspects of these studies are discussed in presented paper.

 

Key words

renal cancer, immunotherapy, PD-1 inhibitor, PD-L1 inhibitor, targeted therapy

 

 

The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...

 

MORE ABOUT SUBSCRIPTION